TRAC and graft versus host disease: Recently, CRISPR/Cas9-mediated knockout of endogenous TRAC or β2M, an essential subunit of HLA-I proteins, has led potently to the defeat of the GVHD progress as well as possible rejection following CAR-T cell therapy (Table 2) (Figure 1) (Li et al., 2020b).